Pritesh Shah's most recent trade in NovoCure Ltd was a trade of 382 Ordinary Shares done at an average price of $12.6 . Disclosure was reported to the exchange on Nov. 7, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Sale of securities on an exchange or to another person at price $ 12.65 per share. | 07 Nov 2023 | 382 | 124,511 (0%) | 0% | 12.6 | 4,832 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Sale of securities on an exchange or to another person at price $ 21.82 per share. | 01 Sep 2023 | 273 | 124,893 (0%) | 0% | 21.8 | 5,956 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 35.28 per share. | 30 Jun 2023 | 367 | 125,166 (0%) | 0% | 35.3 | 12,948 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Sale of securities on an exchange or to another person at price $ 76.16 per share. | 03 Mar 2023 | 16,909 | 124,799 (0%) | 0% | 76.2 | 1,287,779 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Sale of securities on an exchange or to another person at price $ 76.16 per share. | 03 Mar 2023 | 2,942 | 141,708 (0%) | 0% | 76.2 | 224,061 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Sale of securities on an exchange or to another person at price $ 76.16 per share. | 03 Mar 2023 | 1,570 | 144,650 (0%) | 0% | 76.2 | 119,570 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 43,246 | 146,220 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 3,936 | 102,974 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Sale of securities on an exchange or to another person at price $ 75.28 per share. | 02 Mar 2023 | 937 | 99,038 (0%) | 0% | 75.3 | 70,535 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 31,691 | 31,691 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 19,055 | 101,898 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Growth Officer | Sale of securities on an exchange or to another person at price $ 76.36 per share. | 28 Feb 2023 | 1,923 | 99,975 (0%) | 0% | 76.4 | 146,845 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 108.00 per share. | 05 Jan 2023 | 387 | 82,843 (0%) | 0% | 108 | 41,796 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 79.04 per share. | 02 Sep 2022 | 269 | 83,230 (0%) | 0% | 79.0 | 21,261 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 59.07 per share. | 05 Jul 2022 | 312 | 83,499 (0%) | 0% | 59.1 | 18,431 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 69.55 per share. | 07 Mar 2022 | 5,294 | 84,389 (0%) | 0% | 69.6 | 368,198 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 70.10 per share. | 07 Mar 2022 | 2,481 | 81,908 (0%) | 0% | 70.1 | 173,918 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 38,027 | 38,027 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 21,714 | 95,226 (0%) | 0% | 0 | Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 6,231 | 6,231 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 73.34 per share. | 03 Mar 2022 | 2,632 | 91,597 (0%) | 0% | 73.3 | 193,031 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 70.41 per share. | 03 Mar 2022 | 1,914 | 89,683 (0%) | 0% | 70.4 | 134,759 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 74.50 per share. | 03 Mar 2022 | 997 | 94,229 (0%) | 0% | 74.5 | 74,275 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 138.27 per share. | 02 Sep 2021 | 321 | 73,692 (0%) | 0% | 138.3 | 44,386 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 138.23 per share. | 02 Sep 2021 | 156 | 74,013 (0%) | 0% | 138.2 | 21,564 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 139.24 per share. | 02 Sep 2021 | 150 | 73,542 (0%) | 0% | 139.2 | 20,886 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 140.17 per share. | 02 Sep 2021 | 30 | 73,512 (0%) | 0% | 140.2 | 4,205 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 148.71 per share. | 04 Aug 2021 | 2,063 | 74,169 (0%) | 0% | 148.7 | 306,789 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 149.43 per share. | 03 Aug 2021 | 1,654 | 76,232 (0%) | 0% | 149.4 | 247,157 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 137.12 per share. | 06 Jul 2021 | 154 | 77,886 | - | 137.1 | 21,117 | Restricted Share Units |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 215.00 per share. | 10 Jun 2021 | 23,540 | 77,732 (0%) | 0% | 215 | 5,061,100 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 199.67 per share. | 05 May 2021 | 1,290 | 101,272 (0%) | 0% | 199.7 | 257,574 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2021 | 2,333 | 0 | - | - | Restricted Stock Units | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 204.10 per share. | 03 May 2021 | 2,333 | 103,605 (0%) | 0% | 204.1 | 476,165 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 200.86 per share. | 03 May 2021 | 1,043 | 102,562 (0%) | 0% | 200.9 | 209,493 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 131.09 per share. | 08 Mar 2021 | 3,524 | 101,272 | - | 131.1 | 461,961 | Restricted Share Units |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 130.81 per share. | 08 Mar 2021 | 2,627 | 104,796 | - | 130.8 | 343,627 | Restricted Share Units |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2021 | 13,987 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.15 per share. | 05 Mar 2021 | 13,987 | 111,973 (0%) | 0% | 7.1 | 100,007 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 131.53 per share. | 05 Mar 2021 | 4,550 | 107,423 (0%) | 0% | 131.5 | 598,462 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 137.55 per share. | 03 Mar 2021 | 2,658 | 97,986 | - | 137.6 | 365,619 | Restricted Share Units |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 150.78 per share. | 03 Mar 2021 | 2,174 | 100,644 | - | 150.8 | 327,796 | Restricted Share Units |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 20,004 | 20,004 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 10,886 | 102,818 | - | 0 | Restricted Share Units | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 152.05 per share. | 02 Mar 2021 | 912 | 91,932 | - | 152.1 | 138,672 | Restricted Share Units |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 3,086 | 0 | - | - | Restricted Stock Units | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 149.10 per share. | 27 Feb 2021 | 3,086 | 92,844 (0%) | 0% | 149.1 | 460,123 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2020 | 14,518 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.48 per share. | 29 Oct 2020 | 14,518 | 73,808 (0%) | 0% | 7.5 | 108,595 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.46 per share. | 29 Oct 2020 | 10,037 | 89,758 (0%) | 0% | 11.5 | 115,024 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2020 | 10,037 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.37 per share. | 29 Oct 2020 | 5,913 | 79,721 (0%) | 0% | 14.4 | 84,970 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2020 | 5,913 | 0 | - | - | Options to Buy Ordinary Shares | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 85.39 per share. | 09 Sep 2020 | 27,621 | 71,165 (0%) | 0% | 85.4 | 2,358,629 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 86.07 per share. | 09 Sep 2020 | 700 | 70,465 (0%) | 0% | 86.1 | 60,252 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 85.01 per share. | 02 Sep 2020 | 4,200 | 98,786 (0%) | 0% | 85.0 | 357,054 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 76.81 per share. | 03 Aug 2020 | 2,048 | 101,018 (0%) | 0% | 76.8 | 157,307 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 76.41 per share. | 03 Aug 2020 | 1,669 | 103,066 (0%) | 0% | 76.4 | 127,522 | Ordinary Shares |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2020 | 3,717 | 3,717 | - | - | Restricted Stock Units | |
| NovoCure Ltd | Pritesh Shah | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 76.17 per share. | 31 Jul 2020 | 3,717 | 104,735 (0%) | 0% | 76.2 | 283,124 | Ordinary Shares |